Page 3 - தேசிய புற்றுநோய் மையம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021 April 10, 2021 GMT BOULDER, Colo. (BUSINESS WIRE) Apr 10, 2021 Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (RUCA-J) will be presented during week one of the American Association for Cancer Research Virtual Annual Meeting (AACR), taking place April 10-15, 2021. “We remain committed to understanding how Rubraca may benefit patients with cancer, and the data presented at AACR further enhance our understanding in different patient populations and solid tumor types,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “The Phase 1b RAMP data for the combination of Rubra

United statesArpit raoPatrickj mahaffyKenji tamuraAnna sussmanLisa guitermanBreanna burkartNational cancer center hospitalClovis oncology incNational clinical trials networkNational cancer instituteAlliance for clinical trials in oncologyAlliance for clinicalCommunity research oncology programExchange commissionClinical research